Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | IL1B | P01584 | 1/20 | 0.35 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11888309 | 0.91 | ALOX15 (0.45) | ALDH1A1POLBL3MBTL1MAPTALOX15 | |
| SCHEMBL13258696 | 0.86 | THRB (0.38) | ALDH1A1POLBMAPTALOX15KDM4E | |
| SCHEMBL21251502 | 0.85 | ALDH1A1 (0.36) | ALDH1A1POLBL3MBTL1MAPTALOX15 | |
| SCHEMBL7850983 | 0.85 | MEN1 (0.38) | ALDH1A1POLBL3MBTL1MAPTALOX15 | |
| SCHEMBL501841 | 0.84 | KDM4E (0.45) | ALDH1A1POLBL3MBTL1MAPTALOX15 | |
| SCHEMBL30677181 | 0.84 | KDM4E (0.45) | ALDH1A1POLBL3MBTL1MAPTALOX15 | |
| SCHEMBL6368923 | 0.83 | KDM4E (0.37) | ALDH1A1POLBL3MBTL1MAPTALOX15 | |
| SCHEMBL22511600 | 0.82 | UTS2R (0.32) | ALDH1A1POLBL3MBTL1MAPTALOX15 | |
| SCHEMBL22300324 | 0.82 | MAPT (0.34) | ALDH1A1POLBL3MBTL1MAPTALOX15 | |
| SCHEMBL25654057 | 0.82 | ALOX15 (0.31) | ALDH1A1POLBL3MBTL1MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023129564-A1 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| EP-4134104-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | Eubulus Biotherapeutics Inc. (CN) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| WO-2020156017-A1 | TARGETED UBIQUITINATION DEGRADATION BRD4 PROTEIN COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2020-08-06 | — | — | WO | disclosed |
| WO-2019165189-A1 | PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20180179522-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179522-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | ALDH1A1 4528/4885POLB 3392/4885L3MBTL1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.